Antibacterial mesh: A novel technique involving naturally occurring cellular proteins

Surgical Innovation

Volumn 19, Issue 1, 2012, Pages 20-26

  Yurko, Yuliya ^a   McDeavitt, Kathleen ^a   Kumar, Rohan Satish ^b   Martin, Terri ^a   Prabhu, Ajita ^a   Lincourt, Amy E ^a   Vertegel, Alexey ^a   Heniford, B Todd ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

adsorption; antimicrobial protein; lysostaphin; polypropylene mesh; Staphylococcus aureus

Indexed keywords

BETA DEFENSIN 3; CATHELICIDIN; LYSOSTAPHIN; LYSOZYME; POLYPROPYLENE;

ADSORPTION; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL COLONIZATION; BACTERIAL SURVIVAL; COLONY FORMING UNIT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY TEST; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INFLAMMATION; MESH SLING; OPTICAL DENSITY; STAPHYLOCOCCUS AUREUS; TURBIDIMETRY;

ADSORPTION; ANIMALS; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BETA-DEFENSINS; COLONY COUNT, MICROBIAL; HUMANS; LYSOSTAPHIN; MICE; MURAMIDASE; POLYPROPYLENES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURGICAL MESH; SURGICAL WOUND INFECTION;

EID: 81855206879     PISSN: 15533506     EISSN: 15533514     Source Type: Journal    
DOI: 10.1177/1553350611410716     Document Type: Article

References (33)

1. Luijendijk RW, Hop WC, van den Tol MP, et al. A comparison of suture repair with mesh repair for incisional hernia. N Engl J Med. 2000 ; 343: 392-398
2. Grant AM. Open mesh versus non-mesh repair of groin hernia: meta-analysis of randomised trials based on individual patient data [corrected]. Hernia. 2002 ; 6: 130-136
3. Heniford BT, Park A, Ramshaw BJ, Voeller G. Laparoscopic repair of ventral hernias: nine years' experience with 850 consecutive hernias. Ann Surg. 2003 ; 238: 391-399
4. Rios A, Rodriguez JM, Munitiz V, Alcaraz P, Perez Flores D, Parrilla P. Antibiotic prophylaxis in incisional hernia repair using a prosthesis. Hernia. 2001 ; 5: 148-152
5. Chavarriaga LF, Lin E, Losken A, et al. Management of complex abdominal wall defects using acellular porcine dermal collagen. Am Surg. 2010 ; 76: 96-100
6. Cobb WS, Carbonell AM, Kalbaugh CL, Jones Y, Lokey JS. Infection risk of open placement of intraperitoneal composite mesh. Am Surg. 2009 ; 75: 762-767
7. Forbes SS, Eskicioglu C, McLeod RS, Okrainec A. Meta-analysis of randomized controlled trials comparing open and laparoscopic ventral and incisional hernia repair with mesh. Br J Surg. 2009 ; 96: 851-858
8. Harold K, Mekeel K, Spitler J, et al. Outcomes analysis of laparoscopic ventral hernia repair in transplant patients. Surg Endosc. 2009 ; 23: 1835-1838
9. Lin HJ, Spoerke N, Deveney C, Martindale R. Reconstruction of complex abdominal wall hernias using acellular human dermal matrix: a single institution experience. Am J Surg. 2009 ; 197: 599-603
10. Farrow B, Awad S, Berger DH, et al. More than 150 consecutive open umbilical hernia repairs in a major Veterans Administration Medical Center. Am J Surg. 2008 ; 196: 647-651
11. Petersen S, Henke G, Freitag M, Faulhaber A, Ludwig K. Deep prosthesis infection in incisional hernia repair: predictive factors and clinical outcome. Eur J Surg. 2001 ; 167: 453-457
12. Cobb WS, Paton BL, Novitsky YW, et al. Intra-abdominal placement of antimicrobial-impregnated mesh is associated with noninfectious fever. Am Surg. 2006 ; 72: 1205-1208
13. Ganz T. Antimicrobial polypeptides. J Leukoc Biol. 2004 ; 75: 34-38
14. Kagan BL, Ganz T, Lehrer RI. Defensins: a family of antimicrobial and cytotoxic peptides. Toxicology. 1994 ; 87: 131-149
15. Burton MF, Steel PG. The chemistry and biology of LL-37. Nat Prod Rep. 2009 ; 26: 1572-1584
16. Bastos MC, Ceotto H, Coelho ML, Nascimento JS. Staphylococcal antimicrobial peptides: relevant properties and potential biotechnological applications. Curr Pharm Biotechnol. 2009 ; 10: 38-61
17. Gristina AG, Naylor P, Myrvik Q. Infections from biomaterials and implants: a race for the surface. Med Prog Technol. 1988 ; 14: 205-224
18. Cochrane DM, Brown MR, Anwar H, Weller PH, Lam K, Costerton JW. Antibody response to Pseudomonas aeruginosa surface protein antigens in a rat model of chronic lung infection. J Med Microbiol. 1988 ; 27: 255-261
19. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999 ; 284: 1318-1322
20. Phadke SM, Deslouches B, Hileman SE, Montelaro RC, Wiesenfeld HC, Mietzner TA. Antimicrobial peptides in mucosal secretions: the importance of local secretions in mitigating infection. J Nutr. 2005 ; 135: 1289-1293
21. Chen X, Niyonsaba F, Ushio H, et al. Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci. 2005 ; 40: 123-132
22. Centers for Disease Control and Prevention. Preventing emerging infectious diseases: a strategy for the 21st century. http://www.cdc.gov/mmwr/ pdf/rr/rr4715.pdf. Accessed January 17, 2011.
23. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother. 2003 ; 47: 3407-3414
24. Shah A, Mond J, Walsh S. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization. Antimicrob Agents Chemother. 2004 ; 48: 2704-2707
25. Shimoda M, Ohki K, Shimamoto Y, Kohashi O. Morphology of defensin-treated Staphylococcus aureus. Infect Immun. 1995 ; 63: 2886-2891
26. Kumar JK. Lysostaphin: an antistaphylococcal agent. Appl Microbiol Biotechnol. 2008 ; 80: 555-561
27. Kokai-Kun JF, Chanturiya T, Mond JJ. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother. 2009 ; 64: 94-100
28. Placencia FX, Kong L, Weisman LE. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin. Pediatr Res. 2009 ; 65: 420-424
29. Van Hekken DL, Wall RJ, Somkuti GA, Powell MA, Tunick MH, Tomasula PM. Fate of lysostaphin in milk from individual cows through pasteurization and cheesemaking. J Dairy Sci. 2009 ; 92: 444-457
30. Climo MW, Ehlert K, Archer GL. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001 ; 45: 1431-1437
31. Boyle-Vavra S, Carey RB, Daum RS. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate. J Antimicrob Chemother. 2001 ; 48: 617-625
32. Grundling A, Missiakas DM, Schneewind O. Staphylococcus aureus mutants with increased lysostaphin resistance. J Bacteriol. 2006 ; 188: 6286-6297
33. Kusuma C, Jadanova A, Chanturiya T, Kokai-Kun JF. Lysostaphin-resistant variants of Staphylococcus aureus demonstrate reduced fitness in vitro and in vivo. Antimicrob Agents Chemother. 2007 ; 51: 475-482